ATE474602T1 - Verfahren zur behandlung von hiv-infektion - Google Patents

Verfahren zur behandlung von hiv-infektion

Info

Publication number
ATE474602T1
ATE474602T1 AT05723932T AT05723932T ATE474602T1 AT E474602 T1 ATE474602 T1 AT E474602T1 AT 05723932 T AT05723932 T AT 05723932T AT 05723932 T AT05723932 T AT 05723932T AT E474602 T1 ATE474602 T1 AT E474602T1
Authority
AT
Austria
Prior art keywords
hiv infection
treating hiv
treating
infection
hiv
Prior art date
Application number
AT05723932T
Other languages
German (de)
English (en)
Inventor
Pin-Fang Lin
Beata Nowicka-Sans
Gregory Yamanaka
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE474602(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE474602T1 publication Critical patent/ATE474602T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05723932T 2004-03-24 2005-03-01 Verfahren zur behandlung von hiv-infektion ATE474602T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
PCT/US2005/006277 WO2005102392A2 (en) 2004-03-24 2005-03-01 Combinations for treating hiv infection

Publications (1)

Publication Number Publication Date
ATE474602T1 true ATE474602T1 (de) 2010-08-15

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05723932T ATE474602T1 (de) 2004-03-24 2005-03-01 Verfahren zur behandlung von hiv-infektion

Country Status (30)

Country Link
US (1) US7776863B2 (OSRAM)
EP (1) EP1732604B1 (OSRAM)
JP (1) JP4847441B2 (OSRAM)
KR (1) KR101158140B1 (OSRAM)
CN (1) CN1956720B (OSRAM)
AR (1) AR048333A1 (OSRAM)
AT (1) ATE474602T1 (OSRAM)
AU (1) AU2005235116B2 (OSRAM)
BR (1) BRPI0509140A (OSRAM)
CA (1) CA2561146C (OSRAM)
CY (1) CY1111613T1 (OSRAM)
DE (1) DE602005022420D1 (OSRAM)
DK (1) DK1732604T3 (OSRAM)
ES (1) ES2347801T3 (OSRAM)
GE (1) GEP20104925B (OSRAM)
HR (1) HRP20100434T1 (OSRAM)
IL (1) IL178141A (OSRAM)
IN (1) IN2012DN06436A (OSRAM)
MY (1) MY144318A (OSRAM)
NO (1) NO337116B1 (OSRAM)
NZ (1) NZ549778A (OSRAM)
PE (1) PE20060148A1 (OSRAM)
PL (1) PL1732604T3 (OSRAM)
PT (1) PT1732604E (OSRAM)
RU (1) RU2367439C2 (OSRAM)
SI (1) SI1732604T1 (OSRAM)
TW (1) TWI347184B (OSRAM)
UA (1) UA88463C2 (OSRAM)
WO (1) WO2005102392A2 (OSRAM)
ZA (1) ZA200607959B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
JP5251127B2 (ja) 2005-10-28 2013-07-31 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
PL1961744T3 (pl) 2005-11-18 2013-09-30 Ono Pharmaceutical Co Związek zawierający grupę zasadową oraz jego zastosowanie
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
ES2389478T3 (es) * 2008-06-25 2012-10-26 Bristol-Myers Squibb Company Derivados de dicetopiperidina como inhibidores de la fijación del VIH
CN102131810B (zh) * 2008-06-25 2014-02-26 百时美施贵宝公司 作为抗hiv剂的二酮稠合的吡咯并哌啶类和吡咯并哌嗪类
US20110290821A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
US8450361B2 (en) 2010-08-06 2013-05-28 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
US8912195B2 (en) 2010-12-02 2014-12-16 Bristol-Myers Squibb Company Alkyl amides as HIV attachment inhibitors
PT2670751E (pt) 2011-01-31 2015-07-29 Bristol Myers Squibb Co Métodos de fabrico de um composto profármaco inibidor da fixação do vih e intermediários
EP2696937B1 (en) 2011-04-12 2017-05-17 VIIV Healthcare UK (No.5) Limited Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
WO2013033061A1 (en) 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as hiv attachment inhibitors
EP2751118B1 (en) 2011-08-29 2016-10-12 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
EP2895471B1 (en) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Piperidine amide derivatives as hiv attachment inhibitors
US9655888B2 (en) 2012-08-09 2017-05-23 VIIV Healthcare UK (No.5) Limited Tricyclic alkene derivatives as HIV attachment inhibitors
US9586957B2 (en) * 2013-03-27 2017-03-07 VIIV Healthcare UK (No.5) Limited 2-keto amide derivatives as HIV attachment inhibitors
WO2016210130A1 (en) * 2015-06-23 2016-12-29 Cytodyn Inc. Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1068219E (pt) * 1998-03-02 2007-03-30 Univ North Carolina Derivados acilados de betulina e de di-hidrobetulina, sua preparação e sua utilização
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
HUP0402675A2 (hu) * 2001-12-12 2005-03-29 Bristol-Myers Squibb Co. HIV integráz inhibitor hatású hidroxilaminszármazékok, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
IL161784A0 (en) * 2001-12-21 2005-11-20 Anormed Inc Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Also Published As

Publication number Publication date
EP1732604B1 (en) 2010-07-21
PL1732604T3 (pl) 2010-12-31
RU2006137555A (ru) 2008-04-27
CN1956720B (zh) 2010-12-15
AR048333A1 (es) 2006-04-19
DE602005022420D1 (de) 2010-09-02
PT1732604E (pt) 2010-09-24
CA2561146C (en) 2013-12-24
WO2005102392A3 (en) 2006-07-20
MY144318A (en) 2011-08-29
CY1111613T1 (el) 2015-10-07
PE20060148A1 (es) 2006-03-04
ES2347801T3 (es) 2010-11-04
HRP20100434T1 (hr) 2010-09-30
TWI347184B (en) 2011-08-21
UA88463C2 (ru) 2009-10-26
IL178141A (en) 2010-11-30
IN2012DN06436A (OSRAM) 2015-10-09
JP4847441B2 (ja) 2011-12-28
AU2005235116A1 (en) 2005-11-03
GEP20104925B (en) 2010-03-25
US20050215545A1 (en) 2005-09-29
KR20070011322A (ko) 2007-01-24
DK1732604T3 (da) 2010-11-15
CN1956720A (zh) 2007-05-02
US7776863B2 (en) 2010-08-17
ZA200607959B (en) 2008-06-25
CA2561146A1 (en) 2005-11-03
NO337116B1 (no) 2016-01-25
BRPI0509140A (pt) 2007-09-04
KR101158140B1 (ko) 2012-06-19
NO20064547L (no) 2006-10-06
IL178141A0 (en) 2006-12-31
EP1732604A2 (en) 2006-12-20
SI1732604T1 (sl) 2010-10-29
TW200538117A (en) 2005-12-01
NZ549778A (en) 2010-09-30
JP2007530540A (ja) 2007-11-01
WO2005102392A2 (en) 2005-11-03
AU2005235116B2 (en) 2011-03-31
RU2367439C2 (ru) 2009-09-20
HK1096540A1 (en) 2007-06-01

Similar Documents

Publication Publication Date Title
ATE474602T1 (de) Verfahren zur behandlung von hiv-infektion
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
ATE446792T1 (de) Verfahren zur behandlung von sinuskopfschmerzen
ATE465742T1 (de) Tlr7-liganden zur behandlung von hepatitis c
DE602006018354D1 (de) Verfahren zur behandlung von abnormalem zellwachstum
ATE489955T1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
EP2054047A4 (en) Methods for treating acute acoustic trauma
EP1595852A4 (en) PROCESS FOR TREATING WATER CONTAINING AMMONIACAL NITROGEN
EP1948178A4 (en) TREATMENT OF AURICULAR FIBRILLATION BASED ON P38 INHIBITOR COMPOUNDS
EP2046366A4 (en) METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
ATA17552001A (de) Verfahren zur behandlung säurehältiger abwässer
EP1635801A4 (en) METHODS OF TREATMENT AND PREVENTION OF CARDIAC ARRHYTHMIA
EP2037736A4 (en) METHODS OF TREATING RENAL KYSTIC DISEASES
EP1948675A4 (en) METHODS AND COMPOSITIONS FOR TREATING MARFAN SYNDROME AND RELATED DISORDERS
ATA6612003A (de) Verfahren zur reinigung von abwässern
DE112005002653A5 (de) Verfahren zur Konfiguration von Feldgeräten
EP1786465A4 (en) METHODS FOR DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS
EP1848834A4 (en) PROCESS FOR PROCESSING CUPRIFER MATERIALS
DE502004008042D1 (de) Verfahren zum umformen von blechen
ATE374799T1 (de) Verfahren zur behandlung von pigmenten in partikulärer form
DE602004010548D1 (de) Verfahren zur behandlung von tierhäuten
ATE394369T1 (de) Verfahren zur aufreinigung von mesotrion
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
EP1909806A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF ASTHMATIC SYMPTOMS

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1732604

Country of ref document: EP